Moderna (MRNA) expects regulatory approval for its investigational RSV vaccine for older adults starting in 1H24. Moderna CFO Jamey Mock discusses 4Q earnings, as well as Covid vaccine sales. Moderna has reaffirmed its 2024 product sales outlook. Tune in to find out more about the stock market today.
Market On Close
22 Feb 2024
SHARE
Current show
Mon—Fri at 10:00 am — 11:00 am
Trading 360